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Abstract  94	
Context: The currently applied reference ranges for thyroid function are under debate. Despite evidence 95	
that thyroid function within the reference range is related with several cardiovascular disorders, its 96	
association with the risk of stroke has not been evaluated previously. 97	
Design and Setting: We identified studies through systematic literature search and the Thyroid Studies 98	
Collaboration, a collaboration of prospective cohort studies. Studies measuring baseline thyroid-99	
stimulating hormone (TSH), free thyroxine (FT4) and stroke outcomes were included and we collected 100	
IPD from each study, including thyroid function measurements and incident all stroke (combined fatal 101	
and non-fatal) and fatal stroke. The applied reference range for TSH levels was between 0.45-4.49 102	
mIU/L.  103	
Results: We collected IPD on 43,598 adults with TSH within the reference range from 17 cohorts, with 104	
median follow-up of 11.6 years (interquartile range 5.1-13.9), including 449,908 person-years. Age- and 105	
sex-adjusted pooled HR for TSH was 0.78 (95% Confidence Interval [CI], 0.65-0.95, across the reference 106	
range of TSH) for all stroke and 0.83 (95% CI, 0.62-1.09) for fatal stroke. For the FT4 analyses, the HR 107	
was 1.08 (95% CI, 0.99-1.15, per SD increase) for all stroke and 1.10 (95% CI, 1.04-1.19) for fatal stroke. 108	
This was independent of cardiovascular risk factors including systolic blood pressure, total cholesterol, 109	
smoking and prevalent diabetes.  110	
Conclusion: Higher levels of TSH within the reference range may decrease risk of stroke, highlighting 111	
the need for further research focusing on the clinical consequences associated with differences within the 112	
reference range of thyroid function.   113	
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Introduction 114	
Subclinical hypothyroidism is associated with hypertension, hyperlipidemia, atherosclerosis and an 115	
increased risk of coronary artery disease (CAD) whereas subclinical hyperthyroidism is associated with 116	
an increased risk of atrial fibrillation and CAD (1-4). Subclinical thyroid dysfunction is defined by a 117	
thyroid-stimulating hormone (TSH) outside the reference range with a free thyroxine (FT4) within the 118	
reference range.  119	
However, the currently applied reference ranges for thyroid function are under debate (5,6) as thyroid 120	
function within these reference ranges is also associated with several adverse health outcomes (7-9). A 121	
previous systematic review found that lower TSH values and higher FT4 values within the reference 122	
range are associated with reduced bone mineral density, atrial fibrillation and an increased risk of 123	
fractures (8). Furthermore, higher levels of TSH and lower levels of FT4 within the reference range are 124	
associated with cardiovascular events and an unfavorable metabolic profile (8). On the other hand, a 125	
previous individual participant data (IPD) analysis provided no evidence for a higher risk of coronary 126	
heart disease within the reference range as currently defined (10). 127	
A considerable amount of data exist on the association of thyroid function within the reference range and 128	
cardiovascular risk factors such as atrial fibrillation, hypercholesterolemia and hypertension (8). While 129	
these risk factors related to differences within the reference range are also associated with cardiovascular 130	
disease, few data are available on clinical outcomes and no data are available on the risk of stroke, the 131	
second major vascular cause of morbidity and mortality worldwide (11). A previous study-level meta-132	
analysis on the association  of subclinical thyroid dysfunction and stroke risk included only a small 133	
number of  studies and did not include any analyses on TSH within the reference range (12). Assessing 134	
the consequences of differences within the reference range of thyroid function on clinical outcomes is 135	
important for understanding the definition of the reference range and to improve care and preventive 136	
measures. Furthermore, it can help identify clinical outcomes that need to be addressed in future 137	
randomized controlled trials assessing the benefits and risks of thyroid treatment in subclinical thyroid 138	
dysfunction (13). 139	
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Therefore we aimed to investigate the association between TSH and FT4 differences within the reference 140	
range and the risk of stroke (fatal and non-fatal) in an IPD analysis. An IPD analysis provides the 141	
opportunity to standardize definitions of thyroid function and statistical analyses, include unpublished 142	
data and pool results from several cohorts. Also, an IPD can provide the opportunity to conduct subgroup 143	
analyses due to the large number of events included.  144	
 145	
Material and methods 146	
Data Sources and Study Selection 147	
Studies were identified through the Thyroid Studies Collaboration (TSC). The TSC  is a consortium of 148	
cohorts with thyroid function measurements at baseline and prospective follow-up of cardiovascular 149	
outcomes (1,4,10,14-16). Its primary purpose is to examine the association of subclinical thyroid 150	
dysfunction and cardiovascular disease. Eligible cohorts were originally identified through systematic 151	
literature reviews (1) and this has been described in detail previously (12).  From the 19 cohorts identified 152	
by these two literature searches, 17 cohorts had information available on baseline thyroid function and 153	
follow-up stroke incidence, agreed to participate and were therefore eligible for the current study. No 154	
additional inclusion criteria were applied. None of the cohorts has previously published on the risk of 155	
stroke within the reference range of thyroid function, and 5 cohorts (17-21) previously published on the 156	
association of subclinical thyroid dysfunction and the risk of stroke (Table 1). Investigators from the 17 157	
eligible studies were invited to join the IPD analysis. The local Medical Ethics Committees of each 158	
included study approved the distinct original study protocols, and informed consent was obtained from all 159	
study participants by the original cohort studies. 160	
Data Extraction 161	
We requested individual participant characteristics related to prior cardiovascular risk factors and disease, 162	
including systolic blood pressure, serum total cholesterol, history of diabetes, smoking, previous 163	
cardiovascular disease and previous stroke. We also collected available information on demographic 164	
information (age, sex, race), anthropometric measurements (height and weight), medication use (thyroid 165	
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hormone replacement, lipid-lowering and anti-hypertensive therapy) and the outcome. Individual 166	
participant information from all cohorts were collected and analyzed in one center (Rotterdam, The 167	
Netherlands). The primary outcome measures were all stroke (combined fatal and non-fatal) and fatal 168	
stroke. Stroke was defined according to World Health Organization (WHO) criteria as a syndrome of 169	
rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms 170	
lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin, 171	
including ischemic or hemorrhagic strokes.  172	
Thyroid Function Testing Definition 173	
We used a common definition of the reference range of thyroid function (i.e. euthyroidism) in order to 174	
increase comparability among the different studies and in concordance with previous analyses, (1,4,16) 175	
expert reviews (22,23) and several large cohorts (17,24,25). Euthyroidism was defined as TSH level 176	
between 0.45 and 4.49 mIU/L (1). Most studies used a third-generation TSH radioimmunoassay, but the 177	
Whickham Survey used a first-generation assay that reports higher measured TSH values than current 178	
assays, (26) for which we adjusted the range to 0.5-6.0 mIU/L to define euthyroidism, as previously 179	
described (1,15,27). In addition, the Whickham Survey was the only study to perform total T4 assays 180	
(27); the remainder of the cohorts performed FT4 assays.  181	
For FT4 values, we excluded studies that only measured FT4 in TSH values outside of the reference range 182	
for these analyses (17,20,21,28). In studies that measured FT4 independent of TSH values, we used all 183	
FT4 levels with individuals with TSH in the reference range, not limited by the FT4 reference range.  184	
Data synthesis and Statistical Analysis 185	
We performed a Cox proportional hazards model in each cohort separately to assess the association of 186	
TSH or FT4 continuously with all stroke and fatal stroke (IBM SPSS Statistics for Windows, Version 187	
21.0. Armonk, NY: IBM Corp). We investigated the linearity assumption using cubic restricted splines 188	
(rms package, R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, 189	
version 3.0.2). Due to departure from linearity for the TSH analysis in the 4D cohort (p for non-linearity = 190	
0.03), TSH was log transformed for all continuous analyses (natural logarithm). We found no departure 191	
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from non-linearity in the transformed TSH or any of the FT4 analyses and no threshold effect was 192	
therefore detected. The analyses are presented as Hazard Ratios (HR) across the reference range of TSH 193	
(0.45-4.49 mIU/L). This corresponds to the HR when comparing  participants with a TSH in the upper 194	
limit of the reference range (4.49 mIU/L) to participants with a TSH in the lower limit of the reference 195	
range (0.45 mIU/L). The FT4 analyses were performed in a standardized manner (per SD) as well as per 1 196	
ng/dL increase, for which the Whickham study (27) was excluded. We assessed the proportional hazard 197	
assumption in each cohort for each outcome, by Schoenfeld residual plots and the Schoenfeld test. All 198	
studies met the proportional hazard assumption except for the Birmingham study and PROSPER trial for 199	
the analyses with TSH, for which we performed a sensitivity analysis excluding these two cohorts. There 200	
was no interaction between FT4 and TSH levels for the all stroke events or stroke mortality analyses 201	
(p=0.099 and p = 0.28 respectively), as assessed by introducing an interaction term between FT4 (ng/dL) 202	
and TSH values. 203	
We used a random-effects model according to DerSimonian and Laird (29) to pool outcomes estimates 204	
(two-step approach). Pooled estimates were summarized in forest plots using the metafor package for R 205	
(R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). 206	
Heterogeneity across studies was measured using the I2 statistic and 95% confidence interval (95% CI) 207	
(30).  208	
The primary analyses were adjusted for age and sex. We also conducted multivariable analyses 209	
additionally adjusting for systolic blood pressure, smoking, total cholesterol and diabetes. These 210	
covariates were available in all cohorts except for the Birmingham cohort, where none was available (20). 211	
We conducted multiple imputation of covariates in cohorts when there was ≥ 5% of missing data for the 212	
smoking, total cholesterol, systolic blood pressure or prevalent diabetes covariates, which was the case for 213	
one study (19). We considered the age and sex adjusted analysis the primary analysis because 1) 214	
covariates used in the multivariable analyses could also be considered as mediators 2) it includes all 215	
studies, whereas the multivariable analysis does not include the Birmingham cohort. 216	
	
	
10	
	
In order to evaluate the robustness of our findings and identify possible sources of heterogeneity and 217	
populations at risk, we conducted pre-defined subgroup and sensitivity analyses. We performed stratified 218	
analyses by age, sex, history of stroke, subtype of stroke (including only classified strokes) and race, in 219	
concordance with previous reports (1,4). If the parameter estimates were infinite due to a small number of 220	
events in a stratified study-specific analysis, we used Firth's penalized maximum likelihood bias reduction 221	
method for the Cox proportional hazards model (31,32) to estimate hazard ratios (HRs) and 95% CIs. 222	
For the continuous TSH analyses, we conducted the following sensitivity analyses: 1) excluding 223	
participants who had thyroid-hormone replacement at baseline and during follow-up 2) excluding studies 224	
that included transient ischemic attack as a stroke event 3) excluding studies with self-reported stroke data 225	
4) excluding studies that did not meet the proportional hazard assumption 5) excluding cohorts with 226	
potential co-morbidities (e.g. diabetes patients) and 6) excluding studies without formal adjudication 227	
procedures. We also conducted additional multivariable analyses including prevalent atrial fibrillation, 228	
prevalent cardiovascular disease, body mass index (BMI) or lipid-lowering, and anti-hypertensive therapy 229	
at baseline to the previous multivariable model.	Furthermore, we performed the following methodological 230	
sensitivity analyses: 1) perform the meta-analysis in a two-step approach using the restricted maximum-231	
likelihood estimator also using the metafor package and 2) calculate the risk estimates using a one-step 232	
frailty Cox proportional hazards model (coxme package, R-project, Institute for Statistics and 233	
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2.) We assessed age- and sex-adjusted 234	
funnel plots and conducted Egger tests (33) to evaluate potential publication bias statistically. There was 235	
no specific funding for this study. 236	
 237	
Results 238	
We identified 17 cohorts from the United States (17,21,34), Europe (18,20,24,27,28,35-40), Australia 239	
(25), Brazil (41) and Japan (19) that assessed stroke outcomes prospectively and agreed to share IPD 240	
(Table 1). The included studies provided information on a total of 43,598 participants with thyroid 241	
function within the reference range and a follow-up from 1972 to 2014, a median follow-up ranging 242	
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between 1.5 and 20 years and a total follow-up of 450,684 person-years. All studies, except one (34), 243	
included both female (49.6%) and male participants. All cohorts reported fatal stroke and 12 studies 244	
reported both fatal and non-fatal stroke, contributing to the all stroke analyses among 34,853 participants. 245	
During follow-up, 2271 participants had a stroke, with an incidence rate of 6.3 per 1000 person-years and 246	
907 a fatal stroke with 2.0 per 1000 person-years. The FT4 analyses included 24,888 participants for all 247	
stroke and 32,580 for fatal stroke. Two studies (25,39) used variations of the WHO criteria to define all 248	
stroke and fatal stroke (Supplemental Table 1) and four studies included information on type of stroke 249	
(hemorrhagic versus ischemic) (17,21,28,40). One study (39) used questionnaires for the assessment of 250	
non-fatal stroke. Formal adjudication, defined as having clear criteria for the outcomes that were reviewed 251	
by experts for each potential case, was used for all stroke in six studies (17,21,28,36,42,43) and for fatal 252	
stroke in two additional studies (34,38). 253	
All but three cohorts had information on participants' race (18,24,25). For the additional multivariate 254	
analyses, information on AF at baseline was available for eight studies (17,18,21,25,35,36,39,40,42). 255	
Data on lipid-lowering and hypertensive medications were not available in all but two studies (19,24). 256	
Data on history of cardiovascular disease were not available for two studies (34,35). 257	
All studies provided information on the proportion of participants taking thyroid hormone medication at 258	
baseline. In all but four cohorts, none of the participants used thyroid medication at baseline. In the 259	
cohorts where thyroid medication was used, the proportion varied from 1 to 6%. All but six studies also 260	
provided follow-up information on thyroid hormone replacement use, with a range between 0 and 3%.  261	
The association between TSH and the risk of stroke 262	
The age- and sex-adjusted pooled HR for all stroke was 0.78 (95% CI, 0.65-0.95, across the reference 263	
range of TSH mIU/L) and for fatal stroke 0.83 (95% CI, 0.62-1.09) (Figure 1). This corresponds to a 264	
1.28-fold and 1.20-fold increase in all and fatal stroke risk respectively for a participant with a TSH in the 265	
lower limit of the reference range (0.45 mIU/L) compared to a participant with a TSH in the upper limit 266	
of the reference range (4.49 mIU/L).We found no heterogeneity for the analyses of all stroke or fatal 267	
stroke analyses (I2=0%). Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, 268	
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systolic blood pressure and history of diabetes yielded similar results with a HR of 0.76 (95% CI, 0.63-269	
0.91) for all stroke and 0.78 (95 % CI, 0.58-1.07) for fatal stroke (Table 2). Subsequent subgroup 270	
analyses did not show a differential risk when stratifying by sex, age groups, history of stroke or race 271	
(Table 2). The information on type of stroke was available in a subgroup of 11,192 participants in four 272	
studies (17,21,28,40). Stratifying by type of stroke showed a lower estimate in hemorrhagic fatal stroke 273	
compared to ischemic stroke (HR 0.37, 95% CI 0.12-1.12 vs HR 0.78, 95% CI 0.33-1.80), but with an 274	
insignificant p for interaction (p= 0.30). Sensitivity analyses excluding specific studies or participants 275	
using thyroid hormone replacement therapy did not meaningfully affect the risk estimates (Supplemental 276	
Table 2). Additional adjustment for prevalent atrial fibrillation, prevalent cardiovascular disease (defined 277	
as previous coronary heart disease or stroke), BMI or lipid-lowering and anti-hypertensive therapy did not 278	
attenuate the associations. Estimates derived by the methodological sensitivity analyses were similar to 279	
the results of the two-step random-effects model according to DerSimonian and Laird (Supplemental 280	
Table 3). We did not find any evidence of publication bias for the TSH analyses, either with visual 281	
assessment of age- and sex-adjusted funnel plots or with the Egger test for all stroke (p = 0.75) or fatal 282	
stroke (p = 0.29).  283	
The association between FT4 and the risk of stroke 284	
The age- and sex-adjusted pooled HR for the per SD increase of FT4 and stroke analyses were 1.08 (95% 285	
CI, 0.99-1.15) for all stroke and 1.10 (95% CI, 1.04-1.19) for fatal stroke (Table 3, Figure 2). We found 286	
substantial heterogeneity for the analyses on all stroke (I2=55%) but no heterogeneity for fatal stroke 287	
(I2=0%,). When analyzing the association per 1 ng/dL FT4 increase and risk of stroke, the age- and sex-288	
adjusted pooled HRs were 1.40 (95% CI, 0.95-2.05) for all stroke and 1.44 (95% CI, 1.10-1.89) for fatal 289	
stroke (Supplemental Table 4). Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, 290	
systolic blood pressure and history of diabetes did not change risk estimates substantially (Table 3).  291	
Subsequent subgroup analyses showed a differential risk for the different age categories, where the risk 292	
estimates went from protective to deleterious with increasing age (p for trend 0.024, Table 3). When 293	
stratifying by sex, history of stroke or race no differential effects were detected. Stratifying for type of 294	
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stroke also did not show differential risk (Table 3), but this was only possible in one study that was 295	
included in the FT4 analyses. We did not find any evidence of publication bias for the FT4 and stroke 296	
analyses, either with visual assessment of age- and sex-adjusted funnel plots or with the Egger test for all 297	
stroke (p = 0.41) or for fatal stroke (p = 0.28). 298	
 299	
Discussion 300	
In the current IPD analysis of 43,598 participants from 17 prospective cohort studies, higher levels of 301	
TSH within the reference range of thyroid function were significantly associated with a lower risk of 302	
stroke in age- and sex-adjusted and in multivariable analyses. The analyses concerning the association 303	
between TSH levels and fatal stroke were qualitatively similar but did not reach statistical significance. 304	
The analyses on the association between FT4 and all stroke and fatal stroke support the finding of a 305	
higher risk of stroke with differences within the reference range of thyroid function.  306	
Thyroid dysfunction is defined by the biochemical reference ranges for TSH and FT4. These reference 307	
ranges, defining the normal range, depend on the assay used, the distribution of thyroid measurements in 308	
the population, or both. A thyroid function within the “normal range” would imply that the levels of 309	
circulating thyroid hormone are not accompanied by symptoms, an increased risk of disease or adverse 310	
events. In recent years, the applied reference ranges have been debated in the context of mainly the latter 311	
two: adverse events and diseases. Higher levels of TSH within the reference range are associated with an 312	
increase in systolic and diastolic blood pressure (44,45). Moreover, increased TSH levels within the 313	
reference range are linearly associated with an unfavorable serum lipid profile (46). On the other hand, 314	
lower TSH levels within the reference range are associated with an increased risk of heart failure, 315	
coronary heart disease and atrial fibrillation in an elderly population (7). The arbitrary nature of the cut-316	
offs currently used is an important factor hampering decision making on screening and treatment of 317	
thyroid dysfunction (13). In the context of defining the reference range of thyroid function, our study 318	
provides additional evidence that lower levels of TSH and higher levels of FT4 within the reference range 319	
are associated with a negative clinical outcome, namely stroke, a major cause of morbidity and mortality. 320	
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In contrast to blood pressure or cholesterol, reference ranges for thyroid function are currently based on 321	
distribution in the population rather than risks of major diseases. It is more challenging to establish 322	
reference ranges for thyroid function based on risk of outcomes than for cardiovascular risk factors such 323	
as blood pressure and cholesterol, where the increase in risk mainly occurs for values higher than the 324	
upper limit. However, both low and high thyroid function is associated with clinical disease, also within 325	
the reference range. Furthermore, a previous study from the TSC provided no evidence for a higher risk 326	
of coronary heart disease within the normal reference range as currently defined (10). Also, thyroid 327	
function is not solely associated with cardiovascular disease but also a wide variety of clinical outcomes 328	
including fracture risk and possibly cognitive function decline (7,14). Therefore, future research should 329	
investigate if re-evaluation of the currently used reference ranges for thyroid function is meaningful, and 330	
if so, to what extent this should be done for specific populations or subgroups (e.g. elderly). 331	
Several pathways could explain the relation between thyroid function and stroke. Thyroid hormone has 332	
direct effects on the cardiovascular system and is known to decrease systemic vascular resistance (47), 333	
increase left ventricular contractile function and alter systolic and diastolic cardiac function (48). 334	
Differences in thyroid hormone function are associated with the risk of several cardiovascular risk factors 335	
including hypertension, (49) dyslipidemia (50) and atherosclerosis (51). These changes have also been 336	
reported in subjects with subclinical thyroid dysfunction (42) and some also with differences of thyroid 337	
function within the reference range (44-46). The fact that adjustment for these cardiovascular risk factors 338	
in our multivariable analyses did not substantially alter risk estimates, suggests an effect on the risk of 339	
stroke, which is independent of classical risk factors such as hypertension.  340	
Another explanation might be that the lack of effect of multivariable adjustment is due to residual 341	
confounding or unmeasured mediators. For example, in the current analysis, additional adjustment for 342	
atrial fibrillation, a plausible biological mediator for the association between thyroid function and the risk 343	
of stroke (52), did not alter risk estimates substantially. However, detecting an effect may have been 344	
hampered by the lack of information on prevalent atrial fibrillation in nine studies and insufficient 345	
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incidence information.	There was no sufficient information available on anti-coagulant medication use of 346	
participants, which did not allow for further exploration of possible mediating and confounding effects. 347	
Various abnormalities in the hemostatic system have been reported in overt (53) and subclinical thyroid 348	
dysfunction (54). Hypercoagulability is seen in hyperthyroidism while hypothyroidism has been 349	
associated with mainly hypocoagulability (55,56). Alterations in coagulability and the fibrinolytic system 350	
have been linked to a higher risk of cardiovascular disease (57). Whether hemostasis is also affected 351	
within the reference range of thyroid function is not known but might be one of the pathways that play a 352	
role in the increased risk of stroke associated with differences in thyroid function within the reference 353	
range. Changes in coagulation patterns due to thyroid hormone could imply that thyroid function tending 354	
towards hyperthyroidism might increase the risk of ischemic stroke mainly. We only had a small 355	
subgroup of studies including information on type of stroke (hemorrhagic vs ischemic), limiting our 356	
analysis on type of stroke. The exact mechanism explaining the association between differences in thyroid 357	
function within the reference range and the risk of stroke therefore remains to be determined.  358	
Previous studies have reported that the association of thyroid dysfunction with the risk of cardiovascular 359	
disease is influenced by age or sex. A study on the association of thyroid disorders and stroke found a 360	
decreased risk of ischemic stroke in treated male patients with thyroid disorders, but not in females (Sex-361	
Merker et al).  A study level meta-analysis found that subclinical hypothyroidism was associated with 362	
increased risk of ischemic heart disease and cardiovascular mortality only in younger populations (Razvi 363	
et al). In line, a study in participants of 85 years in the general population, revealed no adverse effects of 364	
abnormally high levels of TSH (Gussekloo et al). In contrast, an IPD meta-analysis of 55 287 participants 365	
did not show significant trend in risk of CHD across different age groups (Rodondi et al). In our study, 366	
stratification by age, sex and race did not reveal differential risk patterns.  It should however be noted that 367	
no study to date has looked at the association of thyroid function within the reference range and stroke by 368	
age or sex and this could be one of the reasons for the discrepancies found between previous literature and 369	
our study.   370	
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The association of TSH with the risk of stroke in participants without a prior history of stroke was similar 371	
to the overall analyses, while in participants with a prior stroke, the association was not present. The total 372	
number of participants with a history of stroke was small and therefore, the power to detect a possible 373	
differential risk between participants with and without history of stroke could have been limited. The risk 374	
of all stroke associated with FT4 levels seemed to increase with older age. However, this finding was not 375	
replicated in the TSH or fatal stroke analyses.  376	
Strengths of our study include the ability to perform an IPD analysis including 43,598 participants from 377	
17 studies, based on published and unpublished data. By performing an IPD analysis we were able to 378	
standardize the definition of reference range thyroid function and covariates within our study for the 379	
analyses. There were differences between the study populations regarding age and sex distribution, 380	
amongst others. Nevertheless, there was limited to no heterogeneity of the outcome estimates between the 381	
studies. This could indicate the robustness of the findings.  382	
Despite the large number of participants, we had limited numbers of events in those with a history of 383	
stroke and only four studies included data on type of stroke. Information needed for certain stratification 384	
and sensitivity analyses e.g. by race or prevalent atrial fibrillation was not available for some cohorts. 385	
Also, there was no information available on anti-coagulant use or anticoagulant factor levels, hampering 386	
analyses concerning possible underlying pathways. Furthermore, TSH and FT4 measurements were 387	
performed only at baseline and data on thyroid medication use during follow-up were not complete, 388	
which could change risk over time, in almost all cohorts and therefore it was not possible to take changes 389	
of thyroid function over time into account. Residual confounding cannot be excluded, as is the case in all 390	
observational studies. 391	
Conclusions 392	
In summary, higher TSH levels within the reference range were associated with a lower risk of all stroke. 393	
The analyses for fatal stroke and FT4 were qualitatively similar. These data provide additional evidence 394	
that differences within the reference range of thyroid function, as currently defined, are associated with an 395	
increased risk of a major adverse event. Future studies should investigate if re-evaluation of the currently 396	
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used reference ranges for thyroid function, which are based on fixed biochemical parameters instead of 397	
health and treatment outcomes and risk of disease and mortality, should be considered. This is pivotal 398	
information when designing randomized controlled trials sufficiently equipped to address possible risks 399	
and benefits of thyroid function treatment. 400	
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Legend of Figures 621	
Figure 1.  The association between TSH and Risk of All Stroke and Fatal Stroke* 622	
 623	
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by 624	
squares and are across the range of TSH (0.45 and 4.49 mIU/L). Sizes of data markers are 625	
proportional to the inverse of the variance of the hazard ratios.  626	
Data for all stroke were available in 12 studies. Three hundred ninety-three participants 627	
were excluded from the analysis of all stroke due to missing follow-up data. Data for fatal 628	
stroke were available in 17 studies. Two hundred sixty-five participants were excluded 629	
from the analysis of fatal stroke, due to missing cause of death.  630	
Abbreviations: TSH = thyroid-stimulating hormone. 631	
 632	
 633	
Figure 2.  The association between standardized FT4 and Risk of All Stroke and Fatal Stroke* 634	
 635	
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by 636	
squares and are per one increase of one standard deviation of FT4. Sizes of data markers 637	
are proportional to the inverse of the variance of the hazard ratios.  638	
Data for all stroke were available in 9 studies. Three hundred eighty-seven participants 639	
were excluded from the analysis of all stroke due to missing follow-up data. Data for fatal 640	
stroke were available in 13 studies. Twenty-seven participants were excluded from the 641	
analysis of fatal stroke, due to missing cause of death.  642	
Abbreviations: FT4 = free thyroxine643	
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years* 
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD)	§ 
Follow-up 
median (IQR) 
Person 
years 
4D Study, 
1998, (18) 
Trial of 
atorvastatin in type 
2 diabetes and 
hemodialysis 
patients, Germany 
 
841 66 (30-83) 368 (43.8) 0 11 (1.3) 1.10 (0.77-1.60) 13.90 pmol/L (2.92) 1.5 (0.2-3.6) 1666 
Birmingham 
Study, 1988, 
(20) 
CDA's aged ≥ 60 y 
from primary care 
practice in 
Birmingham, 
England 
 
1015 69 (60-94) 550 (54.2) 0 NA 1.60 (1.10-1.20) NA 10.2 (5.7-10.6) 8301 
Brazilian 
Thyroid 
Study, 1999, 
(41) 
Adults from 
Japanese descent 
living in São Paulo, 
Brazil 
 
890 56 (30-92) 459 (51.6) 0 NA 1.40 (0.90-2.20) 1.07 ng/dL (0.18) 7.3 (7.1-7.5) 6274 
Busselton 
Health Study, 
1981, (25) 
Adults in 
Busselton, Western 
Australia 
 
1902 50 (18-90) 912 (47.9) 0 11 (0.6) 1.42 (1.00-1.96) 16.35 pmol/L (2.89) 20.0 (19.9-20.0) 33,825 
Cardiovascular 
Health Study, 
1989, (17) 
CDA’s with 
Medicare eligibility 
in 4 US 
communities 
 
2526 71 (64-100) 1488 (58.9) 0 52 (2.1) 2.05 (1.45-2.89) NA 14.1 (8.6-16.4) 31,099 
EPIC-Norfolk 
Study, 1995, 
(24) 
Adults living in 
Norfolk, England 
 
11,986 58 (40-78) 6365 (53.1) 0 NA 1.70 (1.20-2.30) 12.58 pmol/L (3.17) 13.4 (12.6-14.3) 153,766 
Health ABC 
Study, 1997, 
(21) 
CDA’s with 
Medicare eligibility 
in 2 US 
communities 
2170 74 (69-81) 1033 (47.6) 0 37 (1.7) 2.00 (1.37-2.72) NA 11.8 (7.5-12.2) 21,057 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) (continued) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years* 
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD)	§ 
Follow-up 
median (IQR) 
Person 
years 
InCHIANTI 
Study, 1998, 
(35) 
Adults aged 20-102 
years living in 
Chianti geographic 
area, Italy 
 
1049 71 (21-102) 575 (54.8) 11 (1.0) NA 1.38 (0.96-1.98) 1.42 ng/dL (0.29) 9.1 (8.2-9.2) 8435 
Leiden 85-plus 
Study, 1997, 
(36) 
Adults aged 85 
years living in 
Leiden, The 
Netherlands 
 
452 85 (NA) 290 (60.4) 0 6 (1.3) 1.65 (1.15-2.31) 14.5 pmol/L (2.26) 5.2 (2.5-8.5) 2555 
MrOS Study, 
2000, (34) 
Community-
dwelling U.S. men 
aged 65 years and 
older 
 
1410 73 (65-99) 0 83 (5.9) NA 1.97 (1.36-2.72) 0.99 ng/dL (0.15) 12.0 (8.5-12.7) 14,541 
Nagasaki 
Adult Health 
Study, 1984, 
(19) 
Atomic bomb 
survivors in 
Nagasaki, Japan 
 
2342 57 (38-92) 1419 (60.6) 27 (1.2) NA 2.60 (2.00-3.40) 1.45 ng/dL (0.46) 13.0 (12.3-13.7) 28,574 
Pisa cohort, 
2000, (38) 
Patients admitted 
to cardiology 
department in Pisa, 
Italy	II 
 
2695 63 (19-92) 840 (31.2) 0 0 1.53 (1.02-2.30) 1.19 ng/dL (0.24) 2.6 (1.6-3.8) 7326 
PREVEND 
Study, 1997, 
(37) 
Adults living in 
Groningen, The 
Netherlands 
 
2493 46 (28-75) 1255 (50.3) 0 4 (0.2) 1.37 (0.99-1.90) 12.81 pmol/L (2.25) 10.9 (10.6 - 11.1) 24,621 
PROSPER 
trial, 1997, 
(28) 
Trial on the 
benefits of 
pravastatin vs 
placebo in adults 
 
 
4953 75 (69-83) 2403 (48.5) 0 28 (0.6) 1.80 (1.26-2.51) NA 3.3 (3.0 - 3.5) 15,937 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) (continued) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years*	
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD)	§ 
Follow-up 
median (IQR) 
Person 
years 
Rotterdam 
Study, 1989 
(40) 
Adults ≥55 years 
living in 
Rotterdam, The 
Netherlands 
 
1577 68 (55-93) 934 (59.2) 0 NA 1.54 (1.06-2.26) 16.29 pmol/L (2.93) 17.0 (11.2 - 18.9) 23,217 
SHIP Study, 
1997 (39) 
Adults in West 
Pomerania, North-
East of Germany 
 
2977 47 (20-81) 1476 (49.6) 0 90 (3.0) 0.79 (0.61-1.07) 12.67 pmol/L (3.42) 11.3 (10.6 - 11.8) 32,238 
Whickham 
Survey	**, 
1974 (27) 
Adults living in 
and near Newcastle 
upon Tyne, 
England 
 
2320 46 (18-92) 1213 (52.3) 92 (4.0) 54 (2.3) 2.10 (1.20-3.00) 8.41 pmol/L
 
(1.95) 19.0 (15.8-20.0) 37,252 
Overall  43,598 64.9 (18-102) 21,580 (49.6) 213 (0.5) 293 (1.4) 1.65 (1.10-2.40) 
13.6 pmol/L 
(2.6) 11.6 (5.1-13.9) 450,684 
Abbreviations: CDA = community-dwelling adult; IQR = interquartile range (25th-75th percentile); NA = not applicable; FT4 = free thyroxine; TSH = thyroid-stimulating hormone. 
* Participants younger than 18 years of age were not included 
† Participants with missing information on thyroid medication at baseline: Health ABC Study 7, MrOs Study 59, Rotterdam Study 463, Whickham Survey 3 
‡ Participants with missing information on thyroid medication at follow-up: Whickham Survey 1430 
§ 1 pmol/L is 0.0777 ng/dL  
II Excluded patients with acute coronary syndrome or severe illness 
**The Whickham Survey used a first-generation assay for the measurement of TSH and did not measure FT4 but total T4. 
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Table 2. Stratified Analyses for the Associations between TSH and the Risk of All Stroke and Fatal Stroke 
  
All Stroke*   Fatal Stroke† 
  
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) I2 
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) I2 
Total 
Population 
TSH 
 
2271/34,853 0.78 (0.65, 0.95) 0.76 (0.63, 0.91) 0% 907/43,333 0.83 (0.62, 1.09) 0.78 (0.58, 1.07) 0% 
Sex§ Men 1091/16723 0.80 (0.62, 1.07) 0.78 (0.60, 1.02) 0% 422/21874 0.85 (0.50, 1.41) 0.85 (0.50, 1.35) 0% 
 Women 1180/18130 0.78 (0.58, 1.07) 0.75 (0.55, 1.02) 25% 485/21459 0.80 (0.52, 1.25) 0.80 (0.52, 1.22) 12% 
 
p for interaction 
 
0.90 0.85  
 
0.86 0.85  
Age	II 18. – 49 60/8305 0.95 (0.31, 2.86) 1.45 (0.37, 4.17) 0% 12/9,525 0.71 (0.07, 7.47) 1.14 (0.06, 23.85) 0% 
 
50 – 64 358/9145 0.75 (0.47, 1.19) 0.75 (0.47, 1.22) 0% 104/12,303 1.35 (0.55, 3.25) 1.22 (0.48, 3.16) 0% 
 
65 -79 1588/15,667 0.83 (0.67, 1.05) 0.80 (0.63, 1.00) 0% 623/19,198 0.89 (0.62, 1.27) 0.95 (0.85, 1.09) 0% 
 
≥80 265/1736 0.69 (0.40, 1.17) 0.63 (0.36, 1.09) 0% 168/2,307 0.43 (0.22, 0.85) 0.36 (0.17, 0.78) 0% 
 
p for trend 
 
0.66 0.28  
 
0.61 0.43  
Stroke 
history¶ No 1875/31,626 0.78 (0.63, 0.98) 0.75 (0.60, 0.93) 0% 710/36,222 0.71 (0.47, 1.07) 0.71 (0.47, 1.05) 24% 
 Yes 206/1266 1.00 (0.53, 1.83) 1.14 (0.60, 2.20) 0% 92/1440 0.83 (0.26, 2.50) 1.58 (0.47, 5.27) 20% 
 p for interaction  0.47 0.23   0.80 0.22  
Stroke type** Hemorrhagic 129/11,192 0.47 (0.26, 0.83) 0.47 (0.25, 0.89) 5% 87/11,192 0.38 (0.14, 1.07) 0.37 (0.12, 1.12) 27% 
 Ischemic 817/11,192 0.71 (0.50, 1.00) 0.69 (0.48,0.98) 0% 182/11,192 0.69 (0.34, 1.35) 0.78 (0.33-1.80) 0% 
 p for interaction  0.24 0.30   0.34 0.30  
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Race‡‡ White 1430/19,037 0.76 (0.60, 0.95) 0.73 (0.58, 0.91) 0% 520/23,213 0.71 (0.48, 1.02) 0.67 (0.47 1.00) 0% 
 Asian NA NA NA  63/3230 0.48 (0.06, 11.22) 0.62 (0.10, 3.97) 41% 
 Black 150/1090 0.85 (0.26, 2.78) 0.91 (0.41, 1.99) 47% 59/1055 0.95 (0.30, 3.12) 0.89 (0.26, 2.91) 0% 
  p for interaction  0.88 0.60   0.83 0.91  
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone. The HR’s are across the reference range of TSH mIU/L (0.45-4.49) 
*Data were available from 12 studies, 393 participants were excluded due to missing stroke event data. 
† 265 participants were excluded due to missing data on cause of death.  
‡ Adjusted for sex, age, systolic blood pressure, total cholesterol, smoking and prevalent diabetes at baseline. The Birmingham Study was excluded in this analysis because of lack of data on 
cardiovascular risk factors. 
§ These analyses were not adjusted for sex. 
II These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
¶ Information on history of stroke was not available for the Pisa cohort, Birmingham Study and Busselton Health Study. Data concerning history of stroke were missing for 64 participants 
in total. 
** Information on type of stroke was available for the Cardiovascular Health Study, Health ABC Study, PROSPER and the Rotterdam Study.  
‡‡Information on race was not available for the 4D study, Birmingham study. Busselton Health Study and EPIC-Norfolk Study. Excluded 96 participants from MrOs Study due to no events 
in subgroup. 
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 Table 3. Stratified Analyses for the Associations between standardized FT4 and the Risk of All Stroke and Fatal Stroke*  
  
All Stroke†  Fatal Stroke‡  
  
No. events/ 
Total 
participants 
Age and Sex adjusted 
HR (95% CI) 
Multivariable	§ 
HR (95% CI) I2 
No. events/ 
Total 
participants 
Age and Sex adjusted 
HR (95% CI) 
Multivariable	§ 
HR (95% CI) I2 
Total Population 
FT4 per SD 
 
1307/24,888 1.08 (0.99, 1.17) 1.06 (0.99, 1.15) 55% 598/32,580 1.10 (1.04, 1,19) 1.09 (1.02, 1.18) 0% 
Sex	II Men 639/11,848 1.02 (0.94, 1.11) 1.00 (0.92, 1.08) 0% 284/16,651 1.10 (0.99, 1.24) 1.08 (0.96, 1.21) 0% 
 Women 668/13,040 1.10 (0.99, 1.22) 1.10 (1.01, 1.20) 52% 314/15,929 1.12 (1.03, 1.23) 1.12 (1.01, 1.24) 0% 
 
p for interaction  0.27 0.12   0.79 0.65  
Age¶ 18 – 49y 59/8289 0.81 (0.61, 1.07) 0.75 (0.55, 1.03) 0% 12/9507 1.50 (0.62, 3.67) 0.93 (0.32, 2.71) 36% 
 
50 – 64y 342/9019 1.03 (0.93, 1.29) 1.03 (0.84, 1.27) 66% 99/11,929 1.09 (0.88, 1.35) 1.06 (0.84, 1.32) 0% 
 
65 -79y 759/6803 1.12 (1.05, 1.19) 1.10 (1.04, 1.17) 0% 376/9897  1.11 (1.01, 1.22) 1.09 (0.99, 1.21) 0% 
 
≥80 147/777 1.15 (0.98, 1.35) 1.15 (0.96, 1.38) 0% 111/1247 1.12 (0.94, 1.33) 1.09 (0.89, 1.33) 0% 
 
p for trend  0.024 0.015   0.54 0.76  
Stroke history** No 1013/22,446 1.06 (0.95, 1.18) 1.05 (0.95, 1.15) 58% 472/27,256 1.10 (1.02, 1.19) 1.09 (1.00, 1.18) 0% 
 Yes 104/483 1.11 (0.95, 1.29) 1.12 (0.95, 1.32) 0% 60/668 1.07 (0.78, 1.45) 1.15 (0.77, 1.73) 26% 
 p for interaction  0.64 0.51   0.87 0.80  
Stroke type‡‡ Hemorrhagic 17/1577 1.37 (0.82-2.29) 1.15 (0.64-2.07) NA 10/1577 1.15 (0.63-2.12) 1.01 (0.49, 2.07) NA 
 Ischemic 157/1577 1.30 (1.14-1.47) 1.20 (1.06-1.37) NA 39/1577 1.00 (0.71-1.41) 0.90 (0.62-1.28) NA 
 p for interaction  0.84 0.88   0.70 0.77  
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Race§§ White 617/10,208 1.12 (0.99, 1.26) 1.11 (0.99 1.23) 51% 319/14,528 1.13 (1.03, 1.23) 1.10 (1.00 1.21) 0% 
 Asian NA NA NA NA 63/3228 1.27 (0.74, 2.18) 1.27 (0.74, 2.18) 58% 
 Black NA NA NA NA 2/48 0.94 (0.23, 3.88) 1.00 (0.14, 7.09) NA 
  p for interaction  NA NA   0.89 0.87  
Abbreviations: CI, confidence interval; HR, hazard ratio; FT4, free thyroxine. NA, not applicable. The HRs are per one increase in standard deviation of FT4. 
*The Whickham Survey did not measure FT4 but total T4. 
† Data were available from 12 studies, 384 participants were excluded due to missing stroke event data. 
‡27 participants were excluded due to missing data on cause of death.  
§ Adjusted for sex, age, systolic blood pressure, total cholesterol, smoking and prevalent diabetes at baseline.  
II These analyses were not adjusted for sex. 
¶ These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
** Information on stroke history was not available for the Pisa cohort, Birmingham Study and Busselton Health Study. Data on stroke history were missing for 64 subjects.  
‡‡ Information on type of stroke was available for the Rotterdam Study. 
§§Information on race was not available for the 4D study, Busselton Health Study and EPIC-Norfolk Study. Excluded 96 participants from MrOs Study due to no events in subgroup. 
	
